Jump to Navigation
Skip to main content
Give Now
Follow Us on Twitter
Follow Us on Instagram
Watch us on YouTube
Follow Us on LinkedIn
Subscribe to our email list
UCLA Stemcell RSS Feed
Search form
Search
Eli and Edythe Broad Center of
Regenerative Medicine and Stem Cell Research
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
About Us
Mission
Milestones
About the Broads
Leadership & Key Members
Stem Cell FAQs & Resources
Contact
Careers
Research & Facilities
Research Areas
Publications
Research Funding
Oversight & Review
Shared Resources & Facilities
Clinical Trials
Alpha Clinic
Current Clinical Trials
Education & Training
Training Programs
Classes & Clubs
Seminars
News, Events, Videos
Newsroom
Event Calendar
Annual Stem Cell Symposium
Videos
Join Us
Give Now
Annual Fund
Innovation Fund
Training Fund
Donor FAQs
Subscribe to Our Emails
Menu
About Us
Mission
Milestones
About the Broads
Leadership & Key Members
Stem Cell FAQs & Resources
Contact
Careers
Research & Facilities
Research Areas
Publications
Research Funding
Oversight & Review
Shared Resources & Facilities
Clinical Trials
Alpha Clinic
Current Clinical Trials
Education & Training
Training Programs
Classes & Clubs
Seminars
News, Events, Videos
Newsroom
Event Calendar
Annual Stem Cell Symposium
Videos
Join Us
Give Now
Annual Fund
Innovation Fund
Training Fund
Donor FAQs
Subscribe to Our Emails
Cancer
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)
Read more
about Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Read more
about CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic
Read more
about A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies
Read more
about Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma
Read more
about Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma
A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC
Read more
about A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC